The OlympiA trial was a large international randomized trial that evaluated 1 year of adjuvant olaparib vs. placebo after chemotherapy and local treatment in gBRCAm carriers with HER2-negative breast cancer and a high risk of recurrence1 (Fig. 1). The gene discussed is ERBB2; the disease is breast cancer.